Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.
McNeil BK, Sorbellini M, Grubb RL 3rd, Apolo A, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, Netto GJ, Shih J, Linehan WM, Pinto PA, Bottaro DP. McNeil BK, et al. Among authors: bottaro dp. J Transl Med. 2014 Oct 21;12:199. doi: 10.1186/1479-5876-12-199. J Transl Med. 2014. PMID: 25335552 Free PMC article.
Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.
Srivastava AK, Hollingshead MG, Weiner J, Navas T, Evrard YA, Khin SA, Ji JJ, Zhang Y, Borgel S, Pfister TD, Kinders RJ, Bottaro DP, Linehan WM, Tomaszewski JE, Doroshow JH, Parchment RE. Srivastava AK, et al. Among authors: bottaro dp. Clin Cancer Res. 2016 Jul 15;22(14):3683-94. doi: 10.1158/1078-0432.CCR-15-2323. Epub 2016 Mar 21. Clin Cancer Res. 2016. PMID: 27001313 Free PMC article.
Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.
Srivastava AK, Hollingshead MG, Govindharajulu JP, Covey JM, Liston D, Simpson MA, Peggins JO, Bottaro DP, Wright JJ, Kinders RJ, Doroshow JH, Parchment RE. Srivastava AK, et al. Among authors: bottaro dp. Mol Cancer Ther. 2018 Mar;17(3):698-709. doi: 10.1158/1535-7163.MCT-17-0552. Epub 2018 Feb 14. Mol Cancer Ther. 2018. PMID: 29444985 Free PMC article.
Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Navas T, Pfister TD, Colantonio S, Aziz A, Dieckman L, Saul RG, Kaczmarczyk J, Borgel S, Alcoser SY, Hollingshead MG, Lee YH, Bottaro DP, Hiltke T, Whiteley G, Takebe N, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. Navas T, et al. Among authors: bottaro dp. PLoS One. 2018 Jun 21;13(6):e0199361. doi: 10.1371/journal.pone.0199361. eCollection 2018. PLoS One. 2018. PMID: 29928062 Free PMC article.
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Navas T, Kinders RJ, Lawrence SM, Ferry-Galow KV, Borgel S, Hollingshead MG, Srivastava AK, Alcoser SY, Makhlouf HR, Chuaqui R, Wilsker DF, Konaté MM, Miller SB, Voth AR, Chen L, Vilimas T, Subramanian J, Rubinstein L, Kummar S, Chen AP, Bottaro DP, Doroshow JH, Parchment RE. Navas T, et al. Among authors: bottaro dp. Cancer Res. 2020 Jan 15;80(2):304-318. doi: 10.1158/0008-5472.CAN-18-3539. Epub 2019 Nov 15. Cancer Res. 2020. PMID: 31732654 Free PMC article.
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Kummar S, Srivastava AK, Navas T, Cecchi F, Lee YH, Bottaro DP, Park SR, Do KT, Jeong W, Johnson BC, Voth AR, Rubinstein L, Wright JJ, Parchment RE, Doroshow JH, Chen AP. Kummar S, et al. Among authors: bottaro dp. Invest New Drugs. 2021 Dec;39(6):1577-1586. doi: 10.1007/s10637-021-01138-x. Epub 2021 Jun 28. Invest New Drugs. 2021. PMID: 34180036 Free PMC article. Clinical Trial.
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas.
O'Sullivan Coyne G, Kummar S, Hu J, Ganjoo K, Chow WA, Do KT, Zlott J, Bruns A, Rubinstein L, Foster JC, Juwara L, Meehan R, Piekarz R, Streicher H, Sharon E, Takebe N, Voth AR, Bottaro D, Costello R, Wright JJ, Doroshow JH, Chen AP. O'Sullivan Coyne G, et al. Clin Cancer Res. 2022 Jan 15;28(2):279-288. doi: 10.1158/1078-0432.CCR-21-2480. Epub 2021 Oct 29. Clin Cancer Res. 2022. PMID: 34716194 Free PMC article.
Targeting the c-Met signaling pathway in cancer.
Peruzzi B, Bottaro DP. Peruzzi B, et al. Among authors: bottaro dp. Clin Cancer Res. 2006 Jun 15;12(12):3657-60. doi: 10.1158/1078-0432.CCR-06-0818. Clin Cancer Res. 2006. PMID: 16778093 Review.
Targeting the Met signaling pathway in renal cancer.
Giubellino A, Linehan WM, Bottaro DP. Giubellino A, et al. Among authors: bottaro dp. Expert Rev Anticancer Ther. 2009 Jun;9(6):785-93. doi: 10.1586/era.09.43. Expert Rev Anticancer Ther. 2009. PMID: 19496715 Free PMC article. Review.
149 results